Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
出版年份 2022 全文链接
标题
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
作者
关键词
-
出版物
NATURE MEDICINE
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-10-07
DOI
10.1038/s41591-022-02031-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
- (2022) Hung Fu Tseng et al. NATURE MEDICINE
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
- (2022) Matthew Gagne et al. CELL
- Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
- (2022) Hana M. El Sahly et al. JOURNAL OF INFECTIOUS DISEASES
- Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
- (2022) Laurence Chu et al. NATURE MEDICINE
- Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity
- (2022) Peter V. Markov et al. NATURE REVIEWS MICROBIOLOGY
- mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
- (2022) Paulina Kaplonek et al. Science Translational Medicine
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19
- (2022) Spyros Chalkias et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
- (2021) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
- (2021) Mark G. Thompson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
- (2021) Mark G. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- (2021) Hana M. El Sahly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
- (2021) Amarendra Pegu et al. SCIENCE
- Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
- (2021) Kathryn M. Hastie et al. SCIENCE
- Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
- (2021) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Origin and evolution of pathogenic coronaviruses
- (2018) Jie Cui et al. NATURE REVIEWS MICROBIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now